Abstract:Abstract Background Glioblastoma multiforme (GBM), a lethal brain tumor, remains the most daunting challenge in cancer therapy. Overexpression and constitutive activation of PDGFs and PDGFRα are observed in most GBM; however, available inhibitors targeting isolated signaling pathways are minimally effective. Therefore, better understanding of crucial mechanisms underlying GBM is needed for developing more effective targeted therapies. Methods Target genes controlled by HIF1α in GBM were identified by analysis of TCGA database and by RNA-sequencing of GBM cells with HIF1α knockout by sgRNA-Cas9 method. Functional roles of HIF1α, PDGFs and PDGFRs were elucidated by loss- or gain-of-function assays or chemical inhibitors, and compared in response to oxygen tension. Pharmacological efficacy and gene expression in mice with intracranial xenografts of primary GBM were analyzed by bioluminescence imaging and immunofluorescence. Results HIF1α binds the PDGFD proximal promoter and PDGFRA intron enhancers in GBM cells under normoxia or mild-hypoxia to induce their expression and maintain constitutive activation of AKT signaling, which in turn increases HIF1α protein level and activity. Paradoxically, severe hypoxia abrogates PDGFRα expression despite enhancing HIF1α accumulation and corresponding PDGF-D expression. Knockout of HIF1A , PDGFD or PDGFRA in U251 cells inhibits cell growth and invasion in vitro and eradicates tumor growth in vivo. HIF1A knockdown in primary GBM extends survival of xenograft mice, whereas PDGFD overexpression in GL261 shortens survival. HIF1α inhibitor Echinomycin induces GBM cell apoptosis and effectively inhibits growth of GBM in vivo by simultaneously targeting HIF1α-PDGFD/PDGFRα-AKT feedforward pathway. Conclusions HIF1α orchestrates expression of PDGF-D and PDGFRα for constitutive activation of AKT pathway and is crucial for GBM malignancy. Therefore, therapies targeting HIF1α should provide an effective treatment for GBM.

DYRK1A activates NFATC1 to increase glioblastoma migration

Circadian Regulator NR1D2 Regulates Glioblastoma Cell Proliferation and Motility

Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function

NRBP1 promotes malignant phenotypes of glioblastoma by regulating PI3K/Akt activation

GDNF triggers proliferation of rat C6 glioma cells via the NF-κB/CXCL1 signaling pathway

DRR1 promotes glioblastoma cell invasion and epithelial-mesenchymal transition via regulating AKT activation

Upregulated FKBP1A Suppresses Glioblastoma Cell Growth Via Apoptosis Pathway

Paired related homeobox 1 transactivates dopamine D2 receptor to maintain propagation and tumorigenicity of glioma-initiating cells

NDR1 Functions As Tumor Suppressor in Glioblastoma by Phosphoralation of YAP

Notch1 Promotes Glioma Cell Migration and Invasion by Stimulating Β‐catenin and NF‐κB Signaling Via AKT Activation

NKCC1 Promotes EMT-like Process in GBM Via RhoA and Rac1 Signaling Pathways.

Rab32 promotes glioblastoma migration and invasion via regulation of ERK/Drp1-mediated mitochondrial fission

Netrin-1 Promotes Glioma Growth by Activating NF-κB Via UNC5A

Activation of JNK and P38 MAPK Mediated by ZDHHC17 Drives Glioblastoma Multiforme Development and Malignant Progression.

Downregulation of RNF138 Inhibits Cellular Proliferation, Migration, Invasion and EMT in Glioma Cells Via Suppression of the Erk Signaling Pathway

A Specific Isoform of Glial Cell Line‐derived Neurotrophic Factor Family Receptor Alpha 1 Regulates RhoA Expression and Glioma Cell Migration

FYN-mediated phosphorylation of BCKDK at Y151 promotes GBM proliferation by increasing the oncogenic metabolite N-acetyl-L-alanine

PPFIBP1 induces glioma cell migration and invasion through FAK/Src/JNK signaling pathway

ERK and PI3K Signaling Cascades Induce Nrf2 Activation and Regulate Cell Viability Partly Through Nrf2 in Human Glioblastoma Cells.

The HIF1α-PDGFD-PDGFRα axis controls glioblastoma growth at normoxia/mild-hypoxia and confers sensitivity to targeted therapy by echinomycin

RRAGB-mediated suppression of PI3K/AKT exerts anti-cancer role in glioblastoma